Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT03123614Phase 4Completed
Phase 4, randomised, open-label trial of loteprednol etabonate ophthalmic gel 0.38% in corneal haze (2 arms), sponsored by University of Utah. Primary endpoint: Change in Intraocular Pressure From Baseline Through Month 3. Started Sep 2014; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT03123614.